A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study
ConclusionsIn the Japanese ERA 223 subgroup, concurrent treatment with AAP and radium-223 did not significantly improve SSE-FS and increased the incidence of fracture, similar to outcomes achieved in the overall population, while an increased incidence of death was not evident. The combination of radium-223 with AAP is not recommended in Japanese patients with asymptomatic or mildly symptomatic mCRPC and bone metastases.Clinical trial registrationClinical trial registration no: NCT02043678.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Japan Health | Oral Cancer | Orthopaedics | Prednisolone | Prednisone | Prostate Cancer | Study